Myriad Genetics Revenue Drops 11% Amid Payer Friction and Volume Challenges
Event summary
- Myriad Genetics reported a revenue decline of 11% year-over-year to $190.7 million in Q2 2026, driven by a 1% drop in volume and a 9% decrease in average revenue per test.
- The company's Cancer Care Continuum business saw a 6% year-over-year increase in test volume growth, supported by the launch of Prolaris + AI and expansion of Precise MRD to include colorectal and renal cancers.
- Prenatal Health revenue declined by 16% year-over-year due to a 9% decrease in volume.
- Myriad Genetics engaged a leading professional services firm to support initiatives aimed at increasing efficiency, scalability, and profitability.
The big picture
Myriad Genetics is navigating a challenging landscape marked by payer friction and volume declines in key segments. The company's strategic initiatives, including the Ascend program and product portfolio review, aim to address these issues and position it for improved profitability and growth. The broader industry trend towards precision medicine and AI-enabled diagnostics underscores the importance of Myriad Genetics' focus on innovation and operational efficiency.
What we're watching
- Revenue Recovery
- Whether Myriad Genetics can mitigate payer friction and improve reimbursement predictability to stabilize revenue growth.
- Operational Efficiency
- The effectiveness of the Ascend initiative in driving increased efficiency, scalability, and profitability.
- Product Portfolio Optimization
- How the rigorous evaluation of Myriad Genetics' product portfolio will impact capital allocation and shareholder value enhancement.
Related topics